tanshinone has been researched along with Carcinoma, Squamous Cell of Head and Neck in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Li, M; Li, W; Liu, W; Zhao, Q; Zuo, H | 1 |
| Gao, F; Han, S; Li, M; Li, W; Liu, H; Liu, W; Zhao, Q; Zhou, L | 1 |
2 other study(ies) available for tanshinone and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis.
Topics: Abietanes; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Proto-Oncogene Proteins c-akt; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2020 |
Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance.
Topics: Abietanes; Animals; Apoptosis; Aurora Kinase B; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; Mice, Nude; Molecular Docking Simulation; Mouth Neoplasms; Protein Binding; Protein Kinase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |